Moving Forward in Alzheimer’s Disease: New Management Paradigms for Patients and Healthcare Systems
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is jointly provided by Global Education Group and Integritas Communications.
Program Description
Alzheimer’s disease (AD) is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. The current understanding of the complex pathophysiology of AD has led to the development of therapies that target amyloid β, tau, and neuroinflammation. Despite its prevalence and significant associated medical, psychosocial, and economic burdens, AD often remains undiagnosed and untreated. As new pathophysiology-linked biomarkers become available and incorporated into practice, diagnosis will improve, thus improving management strategies. However, newer management strategies may result in changes to infrastructure, which will impact each clinician’s practice. In this CME Snapshot series, Dr. Turner and Dr. Cohen will examine AD pathophysiology, optimal strategies to screen patients with suspected mild cognitive impairment (MCI) or AD, the differential diagnoses of MCI and AD, current evidence and regulatory status for newer targeted therapies, ongoing health care disparities in the management of these patients, and potential changes to health care systems as new treatment options become available.
Target Audience
The educational design of this activity addresses the needs of neurology, psychiatry, and gerontology specialists involved in the treatment of patients with Alzheimer’s disease (AD).
Modules
Module 1
Moving Forward in Alzheimer’s Disease: Module 1 – Pathophysiology of Alzheimer’s Disease
Faculty Sharon Cohen, MD, FRCPC & R. Scott Turner, MD, PhDCredits Maximum of 0.25 AMA PRA Category 1 Credit™Expiration2022-02-17Begin Activity
Module 2
Moving Forward in Alzheimer’s Disease: Module 2 – Evaluation and Diagnosis of MCI and AD
Faculty Sharon Cohen, MD, FRCPC & R. Scott Turner, MD, PhDCredits Maximum of 0.25 AMA PRA Category 1 Credit™Expiration2022-02-17Begin Activity
Module 3
Moving Forward in Alzheimer’s Disease: Module 3 – Management of AD
Faculty Sharon Cohen, MD, FRCPC & R. Scott Turner, MD, PhDCredits Maximum of 0.25 AMA PRA Category 1 Credit™Expiration2022-02-17Begin Activity
Module 4
Moving Forward in Alzheimer’s Disease: Module 4 – Barriers to Optimizing AD Management
Faculty Sharon Cohen, MD, FRCPC & R. Scott Turner, MD, PhDCredits Maximum of 0.25 AMA PRA Category 1 Credit™Expiration2022-02-17
Begin Activity